Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial

Familial dysbetalipoproteinemia (FD) is a genetic disorder associated with impaired postprandial lipid clearance. The effect of adding bezafibrate to standard lipid-lowering therapy on postprandial and fasting lipid levels in patients with FD is unknown. In this randomized placebo-controlled double-...

Full description

Bibliographic Details
Main Authors: Charlotte Koopal, A. David Marais, Jan Westerink, Yolanda van der Graaf, Frank L.J. Visseren
Format: Article
Language:English
Published: Elsevier 2017-11-01
Series:Journal of Lipid Research
Subjects:
clinical trial
dyslipidemias
hypolipidemic drugs
diet effects/lipid metabolism
cholesterol
type III hyperlipoproteinemia
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520338086

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520338086

Similar Items